The Biogenera team has achieved a major breakthrough in the development of the innovative anti-tumor drug BGA002: a revolutionary drug that targets aggressive tumors in both children and adults, specifically targeting cancer cells and sparing healthy ones.
An Innovation in the Fight Against Cancer.
New scientific data show that BGA002 is able to penetrate and concentrate in aggressive tumors with MYCN gene mutations, exerting potent anti-tumor-specific action. This is done by blocking the MYCN gene, leading to cancer cell death without damaging healthy cells. Tumors treated include Neuroblastoma and Rhabdomyosarcoma in children, and Small Cell Lung Cancer in adults, known to be associated with smoking and among the deadliest.
Acknowledgements and Clinical Perspectives
BGA002 has already obtained Orphan Drug designation from the European Medicines Agency and the U.S. FDA for the treatment of Neuroblastoma and Soft Part Sarcomas, and for Small Cell Cancer of the Lung. This recognition underscores the drug’s revolutionary potential in treating difficult-to-treat cancers.
Toward Upcoming Clinical Studies
The promising preclinical results of BGA002, designed to specifically block the MYCN tumor gene, pave the way for upcoming clinical trials in patients. Phase 1 clinical trials in children with aggressive cancers are scheduled to begin in early 2025, marking a crucial step toward new hope for a cure.
Publication in a Prestige Magazine.
The new scientific data will be published soon in the prestigious international journal “Nucleic Acid Therapeutics,” confirming the relevance and innovation of BGA002 in the global scientific community.
—
Join Biogenera in this exciting phase of development and help transform the fight against cancer. Investing in Biogenera means being part of a momentous change in cancer medicine.
Learn more about our fundraising campaign on Mamacrowd: https://mamacrowd.com/it/
